← Human Trials & Peer-Reviewed Studies
High-dose transdermal nicotine in Parkinson's disease patients: a randomized, open-label, blinded-endpoint evaluation phase 2 study
Plain-language guide to PMID 28960663 (2018): open-label randomized controlled trial study of Therapeutic nicotine (patch, non-peptide), parkinson's disease.
Key Facts
- PMID
- 28960663
- Journal
- European journal of neurology
- Year
- 2018
- Study type
- Randomized Controlled Trial
- Authors
- Villafane G et al. (16 authors)
- DOI
- 10.1111/ene.13474
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide) in the context of parkinson's disease, published as a randomized controlled trial.
Studies of the effects of nicotine on motor symptoms in Parkinson's disease (PD) brought out discordant results.
Who Took Part
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
Forty PD patients were randomly assigned to a treated and untreated arm in an open-label study.
The main outcome measure was the OFF-DOPA Unified Parkinson's Disease Rating Scale (UPDRS) motor score measured on video recordings by raters blinded to the medication status of the patients.
How the Study Was Run
In design terms this was a randomized and open-label study.
The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
Nothing was hidden in this open-label Therapeutic nicotine (patch, non-peptide) study: the participants and staff both knew the treatment.
Final evaluation was performed 6 weeks after washout.
What Was Measured
The subject headings attached to it are Antiparkinson Agents, Endpoint Determination, Nicotine, Nicotinic Agonists, Parkinson Disease, Surveys and Questionnaires and Transdermal Patch.
The authors tagged it with the keywords Parkinson's disease, drug therapy, motor symptoms, neuroprotection, nicotine patch and symptomatic treatment.
What This Means in Plain Language
The paper is a randomized and open-label study of Therapeutic nicotine (patch, non-peptide) in people with parkinson's disease.
The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2018 (European journal of neurology), a journal based in England.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, Parkinson's disease research.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.